209 results about "Tumor targeted" patented technology

The invention discloses a bovine serum albumin combined nano antibody and a preparation method and application thereof, the amino acid sequence of the bovine serum albumin combined nano antibody Nb1 is shown as SEQ.ID No.1, the nano antibody Nb not only has high affinity to bovine serum albumin, but also has good binding activity to both human serum albumin and mouse serum albumin, and the nano antibody Nb has high affinity to human serum albumin and mouse serum albumin. And the antibody has a relatively good broad-spectrum application range, and can be widely applied to the aspects of drug half-life period enhancement, tumor targeted therapy and imaging, immunodetection or diagnosis, recombinant albumin purification or enrichment and the like.

The invention discloses a multi-angle particle therapy system without a rotating rack and a using method thereof, and relates to the technical field of particle therapy equipment, and the treatment system comprises an accelerator, an irradiation system, a control system, a patient supporting system and an imaging system. The patient supporting system comprises a containing and fixing device, a two-dimensional translation system, a rotating system and a multi-degree-of-freedom mechanical positioning system, the containing and fixing device is connected with the two-dimensional translation system, the two-dimensional translation system is connected with the rotating system, and the two-dimensional translation system controls the relative position of a patient and a rotating center; the rotating system rotates a patient to an appointed angle of a treatment plan or cooperates with the imaging system to obtain a three-dimensional image of the patient, and the irradiation system irradiates a tumor target area; the use method comprises the following steps: generating a treatment plan by reconstructing a three-dimensional CT image, and completing irradiation at different angles according to the treatment plan. According to the treatment system, multi-angle irradiation on a patient can be realized under the condition that a rotating rack is not used, and the manufacturing period and cost of the particle treatment system can be reduced.

The invention discloses a tumor radiotherapy dose calibration method, and relates to the technical field of tumor radiotherapy, and the method comprises the steps: collecting multi-modal data in real time through 4D-CT, MRI and the like, extracting dynamic features through space-time registration, calculating a risk organ dose ratio and a tumor target dose deviation rate, and constructing a comprehensive evaluation function. The method has the advantages that the multi-modal dynamic data of the tumor target area are synchronously collected in real time, the space-time joint registration algorithm and the time sequence weight factor are combined, the limitation that existing static calibration depends on fixed parameters is broken through, and the method is suitable for the multi-modal dynamic data of the tumor target area. According to the method, 95% dose coverage of a tumor target region is guaranteed, and meanwhile, organ-endangering peak value receiving amount is controlled within a certain range of a clinical tolerance threshold value, so that the risk of excessive irradiation of normal tissues is reduced, and the radiotherapy dose calibration precision is prompted based on the deviation rate of a traditional method.

The invention discloses a self-adaptive aid decision-making method, system and device for patient radiotherapy, and a medium, and relates to the field of smart medical treatment. The method comprises the following steps: standardizing and preprocessing multi-source original data; performing automatic segmentation and change detection on tumor and normal tissues based on the processed data; delineating a tumor target region and a normal tissue in radiotherapy in a detection result; generating radiation therapy dose distribution according to the sketching result; evaluating the radiation treatment dose distribution by adopting an optimization evaluation method to generate a plurality of alternative treatment schemes; determining an optimal treatment regimen based on the plurality of alternative treatment regimens; and performing radiotherapy based on the optimal treatment scheme, monitoring anatomical changes of the patient in real time in the radiotherapy process, and dynamically adjusting the optimal treatment scheme. According to the invention, a plurality of operations of patient radiotherapy can be effectively integrated, and precision and individuation of patient radiotherapy can be realized, so that complex changes in the treatment process can be better coped with, and the overall treatment effect can be improved.

The invention provides a tumor target pose real-time tracking and predicting method and system, equipment and a medium. An abdominal respiration monitoring device of the system is used for detecting abdominal respiration deformation; the multi-channel array flexible acquisition sensor has deformability and is used for detecting back myoelectricity and pressure change signals; the body surface information acquisition device is used for acquiring chest and abdomen point cloud data of a human body; and the main controller is used for processing data acquired by the abdominal respiration monitoring device, the multi-channel array flexible acquisition sensor and the body surface information acquisition device to obtain a predicted position of an active tumor target region. In order to solve the problem of respiratory movement in the radiotherapy process, back pressure myoelectricity information, abdomen respiratory deformation information and binocular vision information respiratory movement evaluation are adopted, and a mapping relation from in-vitro movement to in-vivo tumor movement is constructed through in-vitro multi-modal data and 4D-CT information in combination with a big data model. And in-vivo tumor pose prediction and evaluation are realized.

The invention belongs to the technical field of nuclear medicine molecular diagnosis and treatment, and discloses a modified CAIX targeting cyclic peptide, a nuclide marker and application of the modified CAIX targeting cyclic peptide in tumor diagnosis and treatment. According to the CAIX targeted cyclic peptide, a rigid bifunctional chelating agent RESCA is introduced to replace a traditional chelating agent, and a sulfonated or alkylated amino acid connector is combined, so that the enzymolysis resistance and in-vivo stability of the probe are remarkably improved. By optimizing the structure of the connector, the lipophilicity is reduced, liver and gall metabolism and non-specific uptake are reduced, and the high uptake rate of tumor target tissues is maintained. The therapeutic nuclide marker of the cyclopeptide can be used for intratumoral irradiation therapy using DOTA or NOTA in combination with an alkylated amino acid linker or an albumin ligand. Experiments show that the marker has high radiochemical purity, excellent pharmacokinetic characteristics and low kidney retention, and is suitable for precise diagnosis and targeted therapy of CAIX high expression tumors such as kidney cancer, colorectal cancer and brain glioma.

The invention discloses an intelligent medical management method and system based on malignant tumor radiotherapy. The method comprises the following steps: acquiring holographic image data corresponding to clinical image data of a patient; inputting the holographic image data into a trained deep learning model to identify a malignant tumor target region and attributes thereof; calculating the dose of radioactive particles based on the malignant tumor target region and the attributes thereof; generating a 3D printing instruction according to the malignant tumor target region; obtaining dose distribution monitoring data of radioactive particles in the treatment area; analyzing the uniformity of radioactive particles according to the dose distribution monitoring data; and according to the malignant tumor target region, the attributes and the uniformity of the radioactive particles, generating a treatment scheme and performing treatment risk assessment. Effective connection of all links can be achieved, the treatment time of a patient is shortened, and the treatment effect is improved.

The invention discloses a metal polyphenol network modified drug-loaded radioactive microsphere as well as a preparation method and application thereof, radionuclides are labeled on different microspheres by a precipitation method or an adsorption method, and the metal polyphenol network is modified on the surface of the radioactive microsphere to improve the nuclide labeling stability and the synchronous drug loading capability of the radioactive microsphere. Subsequently, medicine molecules can be adsorbed to the modified radioactive microspheres to obtain the metal polyphenol network modified medicine-carrying radioactive microspheres. The metal polyphenol network modified drug-loaded radioactive microspheres prepared by the invention can solve the problems of radionuclide non-target shedding and DNA damage repair caused by nuclear drugs, avoid secondary drug administration, ensure that drugs directly and accurately reach tumor targets, and improve the drug delivery efficiency. And the selective internal irradiation therapy based on radioactive microsphere mediation is further promoted to play a more effective tumor treatment effect.

The invention relates to the technical field of tumor image processing, in particular to a method for improving tumor radiotherapy target area sketching precision. The method comprises the following steps: acquiring an edge connecting line for connecting a central pixel point and different edge pixel points in a possible tumor region; according to the gray level distribution of the pixel points on each edge connecting line, the pixel gray level uniformity of each edge connecting line is obtained, and a connecting line cluster is obtained; analyzing the position distribution characteristics of edge connecting lines in different connecting line clusters and the number of the connecting line clusters, and obtaining the overall gray uniformity of each possible tumor region; obtaining the tumor credibility of each tumor possible region by combining the gray distribution of the boundary pixel points in each tumor possible region and the boundary morphological characteristics of each tumor possible region; an optimal tumor area is obtained, and a tumor target area is sketched. According to the invention, the accurate gray scale range of the tumor area is obtained, so that the target area sketching precision is improved.

The invention provides a bispecific antibody targeting CD3 and tumor targets and application thereof. The bispecific antibody comprises a first antigen binding region, a second antigen binding region and an Fc part, the Fc part comprises a first Fc peptide fragment and a second Fc peptide fragment; the first antigen binding region comprises an scFv fragment and a binding protein of a first molecule or a fragment thereof, the binding protein of the first molecule or the fragment thereof is connected with the N end of the scFv fragment, and the C end of the scFv fragment is connected with the N end of the first Fc peptide fragment; the second antigen binding region comprises a binding protein of a second molecule or a fragment thereof, and the binding protein of the second molecule or the fragment thereof is connected with the N end of the second Fc peptide fragment; the first molecule and the second molecule are the same, and the scFv fragment has CD3 binding activity. The bispecific antibody is weak in combination with T cells, strong in combination with tumor cells, good in safety, high in anti-cancer activity and high in clinical application and drug development value.

The invention provides a preparation method and application of a turmeric extracellular vesicle targeted drug delivery system with an anti-colon cancer effect. The engineering system of modifying CELNs and loading DOX by the TCP-1 colon cancer targeting peptide is constructed by extracting curcuma longa extracellular vesicles (CELNs). The system of loading adriamycin through targeted modified turmeric extracellular vesicles has better anti-tumor activity and tumor targeting property, and HE staining and serum detection results show that the system has no significant influence on important tissues, visceral organs and liver functions of mice. And the biological safety is improved while a better treatment effect is achieved.

The invention belongs to the field of tumor drug research, and particularly relates to a cell vesicle co-delivery system, an anti-tumor drug and application. The cell vesicle-like co-delivery system is constructed according to the following steps: co-transfecting a recombinant expression vector of tumor targeting protein or targeting peptide and a recombinant plasmid of circRNA of effector molecules related to pyroptosis to a tool cell, and collecting to obtain the cell vesicle-like co-delivery system, a recombinant expression vector of the tumor targeting protein or the targeting peptide contains a DNA sequence for coding MCP protein, and a recombinant plasmid of circRNA of an effector molecule related to pyroptosis contains a DNA sequence for coding MS2 protein. According to the cell vesicle co-delivery system provided by the invention, tumor cell death is directly induced by delivering the cell death related effector molecule RNA through the cell vesicles, the killing efficiency is high, the side effect is relatively small, and the problems of mass production and drug loading can be solved.

The present invention provides an antibody-drug conjugate, a preparation method thereof, and an application thereof. The structural formula of the antibody-drug conjugate is as follows. Among them, mAb is the anti-HER2 antibody trastuzumab; the conjugate is obtained by Michael addition of the thiol group obtained by reducing the inter-chain disulfide bond of mAb with the linker-irinotecan conjugate LD038; n ranges from 1 to 10. The binding activity and internalization activity of the antibody-drug conjugate to various tumor target cells are not affected; compared with the same type of antibody-drug conjugate, the antibody-drug conjugate PRO1102 synthesized by the preparation method of the antibody-drug conjugate of the present invention shows certain advantages in terms of in vitro cytotoxicity to tumor cells, anti-tumor activity in rats in vivo, and in vivo pharmacokinetics.

The invention provides an mRNA (messenger Ribonucleic Acid) or mRNA-LNP (Leucine Natriuretic Peptide) compound for coding antibody-antigen fusion protein and application thereof, and belongs to the technical field of cell therapy. Wherein the coding frame sequence of the mRNA comprises an antibody sequence, a cleavage sequence and an antigen peptide sequence; wherein the antibody targets a tumor high-expression surface protein, and the antigen is a high-immunogenicity antigen. According to the mRNA-coded antibody-antigen fusion protein, high-expression protein on the surface of a tumor cell is specifically recognized through an antibody, and a high-immunogenicity antigen is introduced into a recognized tumor target cell to mark the tumor cell. The mRNA can be ingested, processed and presented by antigen presenting cells so as to stimulate and activate antigen-specific TCR-T cells in vivo. Therefore, the widely labeled tumor cells can be specifically recognized and killed by the antigen-specific TCR-T cells in vivo.

The invention relates to a tumor target volume segmentation method and device and a storage medium. The method comprises the following steps: acquiring a medical image containing a target tumor; segmenting the target tumor in a spatial dimension according to the medical image to obtain a plurality of first target volumes which are located in the target tumor and are not overlapped; grouping the plurality of first target volumes to obtain a plurality of target volume groups; wherein each target volume group comprises at least one first target volume, and the adjacent first target volumes in the plurality of first target volumes are located in different target volume groups. According to the tumor target volume segmentation method and device and the storage medium provided by the invention, continuous irradiation of adjacent areas can be avoided through differential irradiation of different target volume groups, so that accumulated damage to surrounding normal tissues is reduced.

The invention relates to the technical field of medical nano-materials, and discloses a pH-responsive drug self-delivery nano-system and a preparation method and application thereof.The preparation method comprises the steps that 1, CMNPs is prepared, specifically, through an amidation reaction, the CMNPs are prepared from methotrexate and cis-aconitic anhydride; step 2, synthesizing DSPE-PEG-T12: synthesizing the DSPE-PEG-T12 by virtue of a nucleophilic addition reaction; step 3, preparing a T12 peptide modified erythrocyte membrane; and step 4, preparing T12-RBCM (at) CMNPs: modifying the T12 peptide of the targeted tumor cell transferrin receptor on an erythrocyte membrane, and coating the CMNPs to construct the nano-acquisition system T12-RBCM (at) CMNPs. According to the nano system T12-RBCM (at) CMNPs obtained by the scheme, the tumor cell uptake efficiency can be remarkably improved, cell apoptosis is induced, and proliferation is inhibited; the long-acting circulation and tumor targeting capability is realized, the tumor growth can be effectively inhibited, and the biological safety is good.

The invention belongs to the technical field of nuclear medicine molecular diagnosis and treatment, and discloses a modified CAIX targeting cyclic peptide and a nuclide marker and application thereof. According to the CAIX targeted cyclic peptide, a rigid bifunctional chelating agent RESCA is introduced to replace a traditional chelating agent, and a sulfonated or alkylated amino acid connector is combined, so that the enzymolysis resistance and in-vivo stability of the probe are remarkably improved. By optimizing the structure of the connector, the lipophilicity is reduced, liver and gall metabolism and non-specific uptake are reduced, and the high uptake rate of tumor target tissues is maintained. The cyclic peptide can label a diagnostic nuclide for PET imaging, or a therapeutic nuclide for intra-tumor irradiation therapy, using DOTA or NOTA in combination with an alkylated amino acid linker or an albumin ligand. Experiments show that the marker has high radiochemical purity, excellent pharmacokinetic characteristics and low kidney retention, and is suitable for precise diagnosis and targeted therapy of CAIX high expression tumors such as kidney cancer, colorectal cancer and brain glioma.

The invention relates to the technical field of image processing, in particular to a small intestine capsule endoscope target detection method which comprises the following steps: acquiring a small intestine capsule endoscope image; the method comprises the following steps: constructing an improved RT-DETR network, inserting an SCSA module between a backbone network and a neck network of the RT-DETR, and introducing a DFM module behind a three-branch Fusion module of the neck network; and the improved RT-DETR network adopts a Focaler-IoU loss function. According to the method, the problem that the accuracy of recognizing the tumor target by using the small intestine capsule endoscope image through RT-DETR needs to be further improved is solved.

The invention discloses a brain tumor detection method based on improved YOLO11, which aims at special properties of medical images and clinical requirements of brain tumor detection, and comprises the following steps: firstly, standardizing and dividing brain tumor medical image data; the method comprises the following steps: designing a multi-stage mixed expansion convolution residual module (BTSA-MFE), and embedding the BTSA-MFE modules in a backbone network and a neck network; designing a lightweight medical feature fusion module M IAFA, and embedding an MIAFA module in a backbone network; a medical image specialized dynamic adaptive internal intersection-to-union ratio loss module MDIOU is designed, bounding box regression is adaptively optimized through a tissue density sensing type dynamic proportion adjustment mechanism, and the positioning precision of tumor targets with fuzzy edges and irregular shapes is improved; after training is completed, the brain tumor medical image to be detected is input into the model, the detection result is output, and the detection precision is improved.

Provided herein are radiopharmaceutical compositions and uses thereof. The radiopharmaceutical compositions can comprise one or more stabilizing agents, an aqueous vehicle, and a conjugate that comprises a targeting ligand and a radionuclide bound to a metal chelator. The targeting ligand can be a small molecule compound or a peptide such as a monocyclic peptide. The targeting ligand can be configured to bind with a tumor target. The stabilizing agent can comprise a radiolysis stabilizer, a free metal chelator, and / or a pH stabilizer. Further provided herein are methods of preparing the radiopharmaceutical compositions and methods of treating cancer by administering the described radiopharmaceutical compositions.

The invention belongs to the technical field of cellular immunity, and relates to a non-virus-dependent engineering induced pluripotent stem cell as well as a preparation method and application thereof. A coding gene of a chimeric antigen receptor is inserted into an SIRPA gene on a genome of the engineered induced pluripotent stem cell. According to the invention, iPSC cells are edited in a SIRPA gene position fixed-point insertion mode, simultaneous knockout of SIRPA and integration of an exogenous chimeric antigen receptor CAR are realized, and CAR-iMac can be further induced and differentiated, so that CAR-iMac is differentiated to mononuclear / macrophage tumor targeted cells, the phagocytic ability of CAR-iMac is enhanced, tumor antigens are further presented, the tumor immune microenvironment is improved, and the anti-tumor immunity is enhanced; the method effectively solves the corresponding problem of directly extracting the natural macrophages from the human body, reduces the production cost and the time cost, is beneficial to clinical application, and in addition, utilizes a non-virus-mediated gene editing means to remarkably improve the genetic silencing phenomenon.

The application provides a preparation method of a Chlorella-arsene composite drug delivery system and application thereof. The application prepares arsene nanosheets (ANs) through a liquid phase stripping method, and obtains catechol-polyethyleneimine nanoparticles (CA-PEI) through oxidation self-polymerization. The ANs and the CA-PEI are charge-absorbed to form CA-PEI loaded with ANs (CA-PEI@ANs), and then charge-absorbed with protein nucleus Chlorella (CP), so that a Chlorella-arsene composite drug delivery system (CP@CA-PEI@ANs) is successfully constructed. The preparation operation of the drug delivery system is simple, and the reproducibility is good, and the drug delivery system has a good application prospect. The protein nucleus Chlorella is used as a drug delivery carrier, so that the problems of high cost and complex synthesis process commonly existing in a targeted delivery carrier are solved, and the application has good tumor targeting effect, and is beneficial to better drug efficacy.

The present application relates to the field of immunology, and particularly relates to a novel IL-15 fusion protein and application thereof. The present application provides an IL-15 transmembrane fusion protein, which is applied to NK cells or CAR-NK cells, can significantly enhance the tumor killing function of NK cells and CAR-NK cells, and can effectively promote the proliferation of NK cells and CAR-NK cells. It provides an important basis for developing NK cell products armored by the IL-15 transmembrane fusion protein, which are independent of any tumor target, thereby reducing the cycle and cost of CAR-NK development. Meanwhile, the present application respectively carries out function research in blood tumors expressing CD19 and solid tumors expressing CD276, and the results indicate the broad-spectrum application prospect of the structure in tumors.

The utility model relates to a dynamic mold body dose verification insertion rod and equipment, the dynamic mold body dose verification insertion rod comprises an insertion rod main body and a fixing part, the insertion rod main body is provided with a mounting part, the fixing part is arranged on the mounting part, and the fixing part comprises a first mold body, a second mold body and a third mold body which are stacked; a spherical simulated tumor target body is arranged between the first die body and the second die body, an imaging film is arranged between the second die body and the third die body, and the stacking direction of the first die body, the second die body and the third die body is parallel to the concave direction of the mounting part. According to the invention, the fixing part is formed by stacking and splicing the first mold body, the second mold body and the third mold body, the imaging film is arranged between the second mold body and the third mold body, and the fixing part is arranged in the mounting part of the insertion rod main body, so that when dynamic mold body dose verification is carried out, the mounting is reliable, and point dose verification and dose distribution verification can be carried out at the same time; and the dose verification time is saved.

This invention discloses a KK-LC-1 targeting binding protein and its derivatives, a kit, and applications. The protein sequence of the KK-LC-1 targeting binding protein is shown in one of SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, and SEQ ID No. 5. The KK-LC-1 targeting binding protein of this invention has a molecular weight of only about 17 kDa, approximately one-tenth that of an antibody, exhibiting good tissue penetration. Furthermore, its production process is simple and yields high quantities. The targeting binding protein of this invention demonstrates good targeting activity against KK-LC-1-positive tumors both in vivo and in vitro, and can be used for targeted tumor drug delivery, representing a potential drug for tumor immunotherapy. Simultaneously, a KK-LC-1 serum detection kit was developed using the targeting binding protein, enabling quantitative detection of KK-LC-1 levels in the human body.

Provided is a bispecific antibody targeting CD3 and a tumor target and a use of the bispecific antibody. The bispecific antibody comprises a first antigen binding region, a second antigen binding region, and an Fc portion; the Fc portion comprises a first Fc peptide fragment and a second Fc peptide fragment; the first antigen binding region comprises an scFv fragment and a binding protein or fragment thereof of a first molecule, the binding protein or fragment thereof of the first molecule is linked to the N-terminal of the scFv fragment, and the C-terminal of the scFv fragment is linked to the N-terminal of the first Fc peptide fragment; the second antigen binding region comprises a binding protein or fragment thereof of a second molecule; and the first molecule and the second molecule are the identical, and the scFv fragment has CD3 binding activity.

The application belongs to the field of pharmacy, and particularly relates to a whole-process targeting polypeptide molecule with the functions of targeting brain capillary endothelial cells, tumor neovascular endothelial cells, tumor pseudo vascular, tumor cells and tumor stem cells, a stable and optimized polypeptide molecule, and a modified complex and drug delivery system for tumor diagnosis and treatment. The application prepares a whole-process targeting polypeptide WVAP and a WVAP modified drug and high polymer carrier material, and applies the WVAP to the construction of a drug delivery system for tumor imaging and targeted therapy. The results show that the WVAP can cross the blood-brain barrier, target tumor neovascular and cross the blood-tumor barrier, target tumor pseudo vascular, tumor cells and tumor stem cells; and the nano drug delivery system constructed by the WVAP modified high polymer carrier material can effectively deliver the loaded drug to the brain, target tumor tissues, and significantly improve the anti-tumor efficacy.

This application provides a method for screening inhibitors targeting CYP7A1 and their use in the preparation of anti-liver cancer drugs, relating to the field of tumor targeted drug design technology. The method for screening inhibitors targeting CYP7A1 protein includes: using the crystal structure of human cholesterol 7α-hydroxylase as a receptor model, precise docking screening is performed using software to screen drug-like molecules with molecular weights of 250-500 Da and lipid-water partition coefficients of -1 to 5 from a compound database; a graph neural network active learning model is used to predict and rank the protein-small molecule binding affinity of compounds in the database; the ΔG between candidate molecules and CYP7A1 is calculated using molecular mechanics / generalized Born surface area methods, with molecules having ΔG ≤ -40 kcal / mol considered potential inhibitors. The inhibitors of this application do not rely on the enzymatic activity of CYP7A1 to achieve anti-tumor effects and do not significantly affect cholesterol and bile acid metabolism levels.

The invention discloses a real-time positioning method for a tumor target region and a gold label implant, and belongs to the technical field of tumor localization, and the method specifically comprises the following steps: implanting a gold label in a tumor region, constructing a gold label-tumor dynamic model through CT, and obtaining a respiratory phase feature vector; realizing space matching of the two-dimensional projection and the three-dimensional model by using an improved hybrid registration algorithm, and obtaining a tumor compound displacement vector; establishing a respiration-displacement correlation model through time sequence alignment, generating a tumor movement map containing a real-time position and a predicted trajectory, and updating the reference coordinate system; establishing a rigid safety boundary based on a gold label, analyzing soft tissue texture and a prediction trajectory in combination with a convolutional neural network to generate an elastic treatment boundary, and dynamically adjusting a dose weight of a non-label area; and finally, submillimeter-level dynamic tracking is executed through a multi-leaf collimator. The problems of tumor motion uncertainty and individual deformation difference are solved, and the target area coverage precision and the dose distribution reasonability are improved.

The invention relates to the technical field of medical instrument application, in particular to a universal labyrinth source applicator and a method for realizing multi-angle accurate implantation thereof, and aims to solve the problems of insufficient focus dose coverage, high treatment cost and high efficiency caused by the fact that a bare-handed implantation or printing mold guide implantation mode is generally adopted during cervical cancer radiotherapy. And the cervical cancer radiotherapy effect is finally influenced. According to the method, function design is carried out on the implantation path of the implantation needle of the source applicator, then the source applicator is placed in a mathematical coordinate system, image data are scanned through CT equipment, the vertical distance, namely the transverse implantation range, from the tumor target position to the uterine cavity tube is calculated, and then the depth, needing to enter the tumor, of the implantation needle is calculated according to the number of image layers from the tumor target position to the lower surface of the source applicator. After the needed needle insertion channels are predicted, the multiple needle insertion channels of the labyrinth insertion source applicator are selected for insertion, so that the radioactive source can accurately cover a tumor focus treatment area during tumor after-loading treatment, and the overall treatment effect of cervical cancer is greatly improved.